Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405067 · ClinicalTrials.gov registry record · Phase 2
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
A Phase 2 study of Hypercholesterolemia, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00405067: Completed Phase 2 study of Hypercholesterolemia, sponsored by Aegerion Pharmaceuticals.
NCT00405067 is a Phase 2 study of Hypercholesterolemia that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 60 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00405067, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.
Conditions Studied
Interventions
- DRUG Ezetimibe
- DRUG BMS-201038 (AEGR-733)
Study Locations (1)
New Jersey
- Pharmanet, Inc - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00405067 record still lists
NCT00405067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Ezetimibe is the first listed.
NCT00405067 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00405067 about?
NCT00405067 is a clinical study titled "The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia". The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.
What is the current status of trial NCT00405067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-05. Estimated completion is 2007-01.
What conditions does trial NCT00405067 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT00405067?
The interventions under investigation include: Ezetimibe (DRUG), BMS-201038 (AEGR-733) (DRUG).
Who is sponsoring clinical trial NCT00405067?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00405067 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00405067's enrollment target sits among peer trials
60 50th of 62 higher than 12 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia